News stories about Inflarx (NASDAQ:IFRX) have trended somewhat positive this week, according to Accern. The research firm scores the sentiment of media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Inflarx earned a daily sentiment score of 0.03 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 47.3255906916403 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Shares of Inflarx stock opened at $38.77 on Friday. Inflarx has a 52 week low of $14.47 and a 52 week high of $39.00.

IFRX has been the subject of several research analyst reports. Leerink Swann increased their price objective on shares of Inflarx from $31.00 to $36.00 and gave the company an “outperform” rating in a research report on Monday, April 2nd. B. Riley initiated coverage on shares of Inflarx in a research report on Thursday, February 8th. They issued a “buy” rating and a $40.00 price objective for the company. Finally, Zacks Investment Research lowered shares of Inflarx from a “hold” rating to a “sell” rating in a research report on Saturday, April 7th. One analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $34.25.

ILLEGAL ACTIVITY NOTICE: “Inflarx (IFRX) Receiving Somewhat Positive News Coverage, Report Finds” was first published by Daily Political and is the property of of Daily Political. If you are viewing this article on another site, it was illegally stolen and reposted in violation of US & international copyright laws. The legal version of this article can be viewed at

About Inflarx

Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company’s primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases.

Insider Buying and Selling by Quarter for Inflarx (NASDAQ:IFRX)

Receive News & Ratings for Inflarx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inflarx and related companies with's FREE daily email newsletter.